A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH

The specific pathways, timescales, and dynamics driving the progression of fibrosis in NAFLD and NASH are not yet fully understood. Hence, a mechanistic model of the pathogenesis and treatment of fibrosis in NASH will necessarily have significant uncertainties. The rate of fibrosis progression and t...

Full description

Bibliographic Details
Main Authors:	Lyndsey F. Meyer, Cynthia J. Musante, Richard Allen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Medicine
Subjects:	NAFLD NASH fibrosis progression Markov chain model liver biopsy fibrosis score
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1130890/full

Similar Items

Comparison between NAFLD fibrosis score and retinoic acid serum level in NAFLD
by: Ahmed Samir Allam, et al.
Published: (2020-01-01)

Imaging biomarkers of NAFLD, NASH, and fibrosis
by: Veeral Ajmera, et al.
Published: (2021-08-01)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
by: Wei-Qiang Leow, et al.
Published: (2020-08-01)

Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients
by: Ahmed El Ray, et al.
Published: (2022-08-01)

Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease
by: Antonella Mosca, et al.
Published: (2022-04-01)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
by: Lydie Carreres, et al.
Published: (2021-04-01)

Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)
by: Francesco Vizzutti;, et al.
Published: (2009-04-01)

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4
by: Katharina John, et al.
Published: (2022-07-01)

Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis
by: Jin-Zhong Li, et al.
Published: (2023-12-01)

Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
by: Xinlei Li, et al.
Published: (2023-08-01)

Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
by: Mary Patricia Moore, et al.
Published: (2023-05-01)

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
by: Silvia Sookoian, et al.
Published: (2018-03-01)

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology
by: Anita M. van den Hoek, et al.
Published: (2020-09-01)

From NAFLD to HCC: Advances in noninvasive diagnosis
by: Qinchen Xu, et al.
Published: (2023-09-01)

Judicious Use of Lipid Lowering Agents in the Management of NAFLD
by: Umair Iqbal, et al.
Published: (2018-09-01)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
by: Alexandre Losekann, et al.
Published: (2015-10-01)

Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis
by: Emma L. Shepherd, et al.
Published: (2021-04-01)

Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF)
by: Guodong Zhang, et al.
Published: (2020-10-01)

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
by: Fraile JM, et al.
Published: (2021-09-01)

EZH2 as a Potential Target for NAFLD Therapy
by: Hyun Jung Lim, et al.
Published: (2020-11-01)

Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH
by: David Montefusco, et al.
Published: (2022-08-01)

NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling
by: Yoshiaki Sunami
Published: (2020-09-01)

Factores analíticos, antropométricos y dietéticos asociados al desarrollo de fibrosis en pacientes con enfermedad por hígado graso no alcohólico
by: Sara Gómez-de-la-Cuesta, et al.

Deciphering the role of aberrant DNA methylation in NAFLD and NASH
by: Meenakshi Vachher, et al.
Published: (2022-10-01)

Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk
by: Siarhei A. Dabravolski, et al.
Published: (2021-04-01)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
by: Jian Huang, et al.
Published: (2023-04-01)

Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease
by: Sachiyo Yoshio, et al.
Published: (2021-07-01)

Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients
by: Mohsen M. Maher, et al.
Published: (2015-01-01)

The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features
by: Akira Sasaki, et al.
Published: (2022-02-01)

New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD
by: Louise Torres, et al.
Published: (2023-01-01)

CD4+ T Cells Mediate the Development of Liver Fibrosis in High Fat Diet-Induced NAFLD in Humanized Mice
by: Zhisheng Her, et al.
Published: (2020-09-01)

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
by: Tina Reinson, et al.
Published: (2023-02-01)

Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos
by: S. Marciano, et al.
Published: (2022-01-01)

Early transcriptome changes associated with western diet induced NASH in Ldlr−/− mice points to activation of hepatic macrophages and an acute phase response
by: Jyothi Padiadpu, et al.
Published: (2023-08-01)

Type IV collagen as marker of fibrosis in nonalcoholic liver disease
by: Alvina
Published: (2010-08-01)

Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?
by: Diego García-Compeán, et al.
Published: (2020-05-01)

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
by: Rocío Gallego-Durán, et al.
Published: (2021-11-01)

Interleukin-13 (IL-13)—A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis
by: Elke Roeb
Published: (2023-08-01)

High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients
by: Juan P. Arab, et al.
Published: (2016-09-01)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
by: J.T. Stefano, et al.
Published: (2015-02-01)